Marc Mansour

Marc Mansour brings over 18 years of scientific research and biotech business experience. Prior to joining AELIX as Business Development Consultant, he was Chief Scientific Officer and then Chief Executive Officer at Immunovaccine, Inc., a publicly-traded Canadian company focused on developing cancer immunotherapies and infectious disease vaccines, where he developed and established the company’s clinical programs and strategic clinical collaborations. Dr. Mansour is also Chief Science Officer/ Chief Business Officer at Vaximm, a private company focused on therapeutic cancer vaccines. Dr. Mansour has a Ph.D. in biology from Dalhousie University and an MBA from the Sobey School of Business.